Unipolare Depression Langfassung - Versorgungsleitlinien.de

515. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin
reuptake inhibitors. Clin Pharmacokinet 1996;31(6):444-69.
516. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-
Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major
depression: a multicenter study. Am J Psychiatry 1997;154(7):963-9.
517. Bauer M, Whybrow PC, Angst J. Biologische Behandlung unipolarer depressiver Störungen.
Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP),
Teil 1 und 2. Edition Psychopharmakotherapie. Stuttgart: Wiss. Verl.-ges.; 2004.
518. Fritze J, Aldenhoff J, Maier W, Möller H-J. Antidepressiva: Lebensgefährliche Placebos?
Arznei-Telegramm: fahrlässiges Journal. Nervenarzt 2005;76(11):1432-9.
519. Miller MC. Does the new antidepressant duloxetine (Cymbalta) have any advantages over
other antidepressant drugs? Harv Ment Health Lett 2004;21(5):8.
520. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO,
editor. Treatment of Psychiatric Disorders. 3rd ed. Washington: Am. Psychiatric Publ.; 2001.
p. 1417-39
521. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J
Clin Psychiatry 1993;54 Suppl:39-45.
522. Charney DS, Reynolds CF, III, Lewis L, Lebowitz BD, Sunderland T, Alexopoulos GS, Blazer
DG, Katz IR, Meyers BS, Arean PA, Borson S, Brown C, Bruce ML, Callahan CM, Charlson
ME, Conwell Y, Cuthbert BN, Devanand DP, Gibson MJ, Gottlieb GL, Krishnan KR, Laden SK,
Lyketsos CG, Mulsant BH, Niederehe G, Olin JT, Oslin DW, Pearson J, Persky T, Pollock BG,
Raetzman S, Reynolds M, Salzman C, Schulz R, Schwenk TL, Scolnick E, Unutzer J,
Weissman MM, Young RC. Depression and Bipolar Support Alliance consensus statement on
the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen
Psychiatry 2003;60(7):664-72.
523. Reynolds CF, III, Miller MD, Pasternak RE, Frank E, Perel JM, Cornes C, Houck PR,
Mazumdar S, Dew MA, Kupfer DJ. Treatment of bereavement-related major depressive
episodes in later life: a controlled study of acute and continuation treatment with nortriptyline
and interpersonal psychotherapy. Am J Psychiatry 1999;156(2):202-8.
524. Reynolds CF, III, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR,
Dew MA, Stack JA, Pollock BG, Kupfer DJ. Nortriptyline and interpersonal psychotherapy as
maintenance therapies for recurrent major depression: a randomized controlled trial in patients
older than 59 years. JAMA 1999;281(1):39-45.
525. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake
inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44(2):77-
87.
526. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001;57:145-
59.
527. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB,
Grochocinski VJ. Comparison of full-dose versus half-dose pharmacotherapy in the
maintenance treatment of recurrent depression. J Affect Disord 1993;27(3):139-45.
528. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-
Lucena N, Singer L, Danion JM. The prophylactic efficacy of fluoxetine in unipolar depression.
Br J Psychiatry Suppl 1988;(3):69-76.
529. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg
citalopram, and placebo in the prevention of relapse of major depression. Int Clin
Psychopharmacol 1993;8(3):181-8.
530. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a longterm,
double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13(2):55-62.
531. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse
prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10 Suppl
1:29-35.
© 2009 227